✦ LIBER ✦

Phase II studies of ifosfamide alone and in combination in cancer of the cervix

✍ Scribed by G. Blackledge; E. J. Buxton; J. J. Mould; J. Monaghan; M. Paterson; J. Tobias; C. Alcock; D. Spooner; C. A. Meanwell

Publisher: Springer
Year: 1990
Tongue: English
Weight: 543 KB
Volume: 26
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00685409

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of ifosfamide in advanc

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix

✍ R. E. Coleman; P. G. Harper; C. Gallagher; R. Osborne; E. M. Rankin; A. C. Silve 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 405 KB

A phase II study of ifosfamide in endome

A phase II study of ifosfamide in endometrial cancer

✍ C. Barton; E. J. Buxton; G. Blackledge; J. J. Mould; C. A. Meanwell 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 235 KB

Phase II study of ifosfamide and mesna i

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix

✍ Gregory P. Sutton; John A. Blessing; Leon Adcock; Kenneth D. Webster; Timothy De 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 223 KB

Phase II study of carboplatin/ifosfamide

Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer

✍ H. Kühnle; H. G. Meerpohl; W. Eiermann; S. Röben; L. Lenaz; W. Achterrath 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 232 KB

A phase II study of ifosfamide and cispl

A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

✍ R. E. Coleman; J. M. Clarke; M. L. Slevin; J. Sweetenham; C. J. Williams; P. Bla 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 363 KB

A phase I-II study of docetaxel-ifosfami

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer

✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n